What’s new on the Pulmonary Hypertension Knowledge Sharing Platform – October 2026

October was a busy month for the pulmonary hypertension community. The Alliance for Pulmonary Hypertension added five new PEP Talks and, together with the European Pulmonary Fibrosis Federation (EU-PFF), held a webinar on pulmonary hypertension associated with interstitial lung disease. On the treatment front Gossamer Bio has submitted a New Drug Application (NDA) for seralutinib […]

What’s new on the Pulmonary Hypertension Knowledge Sharing Platform – October 2026 Read Post »

Five new PEP Talks now online in the dedicated section of this website

Have you watched our latest PEP Talks? In the five most recent videos: 🔹 Aygün Mengelli Tomur (Turkey) reflects on life after lung transplantation, gratitude to her donor, and the importance of organ donation. 🔹 Jolie Lizana (USA) draws on her experience as a person living with pulmonary arterial hypertension, her healthcare background, and her

Five new PEP Talks now online in the dedicated section of this website Read Post »

Update on investigational formulation of inhaled rapamycin (mTOR inhibitor) for multiple pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome after lung transplant, October 9, 2026

Quince Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, has announced that it has changed its name to IRulya Therapeutics Inc. IRulya will be focused on advancing LAM-001, an investigational formulation of inhaled rapamycin (mTOR inhibitor) for multiple pulmonary diseases. LAM-001 is a

Update on investigational formulation of inhaled rapamycin (mTOR inhibitor) for multiple pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome after lung transplant, October 9, 2026 Read Post »

United Therapeutics (UTHR) Opens Xeno Organ Production Sites In Houston And Stewartville, Simply Wall Street, October 24, 2026

With its new facilities in Houston and Stewartville, United Therapeutics is turning its organ programme from an idea into a concrete part of the business. Rather than relying only on its lung medicines to grow, the company is now investing in physical sites to build a second line of business: producing organs for transplant alongside

United Therapeutics (UTHR) Opens Xeno Organ Production Sites In Houston And Stewartville, Simply Wall Street, October 24, 2026 Read Post »

Alaunos Therapeutics has bought Velaris Therapeutics, which is developing four biological drugs for pulmonary arterial hypertension (PAH) and related heart and lung diseases, October 13, 2026

The pipeline VLR199 (the lead candidate): works in the same way as sotatercept (Winrevair), by trapping proteins of the activin family that drive the abnormal growth of cells in the lung vessels. The aim is to improve on aspects of sotatercept that may not be “fully optimised”. First clinical results showing whether it works are

Alaunos Therapeutics has bought Velaris Therapeutics, which is developing four biological drugs for pulmonary arterial hypertension (PAH) and related heart and lung diseases, October 13, 2026 Read Post »

Evolving profile and outcomes of patients with pulmonary arterial hypertension (PAH) undergoing lung transplantation in France, Journal of Heart and Lung Transplant, September 3, 2026

A study published in Journal of Heart and Lung Transplant Open by a large French team looked at all 241 patients with pulmonary arterial hypertension who had a lung or heart-lung transplant in France between 2008 and 2023. Using data from the national registries for the disease and for transplants, the authors compared two periods:

Evolving profile and outcomes of patients with pulmonary arterial hypertension (PAH) undergoing lung transplantation in France, Journal of Heart and Lung Transplant, September 3, 2026 Read Post »

October 10 2026 is the Council of Europe’s “European Day for Organ Donation and Transplantation”, the host country this year is Cyprus

October 10, is the European Day for Organ Donation and Transplantation. Created in 1996 by the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe. It’s aim is to raise public awareness of the need for organ, tissue and cell donation, promote voluntary and unpaid donation, and honour donors and healthcare

October 10 2026 is the Council of Europe’s “European Day for Organ Donation and Transplantation”, the host country this year is Cyprus Read Post »

What’s new on the Pulmonary Hypertension Knowledge Sharing Platform – September 2026

September was a busy month in the pulmonary hypertension world, with the European Society of Cardiology (ESC) and European Respiratory Society Congresses (ERS) bringing a wave of new research. The most important news is the update of the ERS Clinical Practice Guidelines for the treatment of pulmonary arterial hypertension (PAH), presented in Barcelona. AfPH Vice

What’s new on the Pulmonary Hypertension Knowledge Sharing Platform – September 2026 Read Post »

Reporting from the European Society of Cardiology (ESC) and European Respiratory Society (ERS) Annual Congresses 2026, Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension

Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension and Chair of the Dutch pulmonary hypertension foundation, attended both the European Society of Cardiology and the European Respiratory Society (ERS) Annual Congresses 2026 taking place respectively in Munich, Germany (August 28-30), and Barcelona, Spain (September 5-9). Based on the sessions she followed, she has

Reporting from the European Society of Cardiology (ESC) and European Respiratory Society (ERS) Annual Congresses 2026, Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension Read Post »

Announcing five new “PEP Talks, part of our ongoing “Patient Empowering Patients” educational video series, September 28, 2026

We are thrilled to release five brand-new “Patients Empowering Patients” talks — five women, three countries (Italy, Turkey, the US), and five very different stories, all united by the same resilience and positive outlook that defines this community. From Aygün Mengelli Tomur’s lung transplant journey “From Waiting to Breathing: A New Beginning,” to Deger Kesimogluğlu’s

Announcing five new “PEP Talks, part of our ongoing “Patient Empowering Patients” educational video series, September 28, 2026 Read Post »

The French Pulmonary Hypertension Associations celebrates its 30th anniversary at its 6th Patient Congress on 13-15 November 2026

The French Pulmonary Hypertension Association HTaPFrance is holding its 6th Patient Congress, 13–15 November 2026 at Centre Valpré in Écully, France — coinciding with the association’s 30th anniversary. The congress is open to pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH patients, those awaiting or having received a transplant, along with their families,

The French Pulmonary Hypertension Associations celebrates its 30th anniversary at its 6th Patient Congress on 13-15 November 2026 Read Post »

Live Webinar on Early Referral for Lung Transplantation: Recognizing the Right Time, CHEST, June 2, 2026, recording now available

A live, case-based webinar held on June 2, 2026 looked at when and how patients with advanced pulmonary disease should be referred for lung transplant evaluation. The expert faculty walked through evidence-based referral criteria, disease-specific considerations, and complex scenarios — including interstitial lung disease, pulmonary arterial hypertension, and critically ill patients in the Intensive Care

Live Webinar on Early Referral for Lung Transplantation: Recognizing the Right Time, CHEST, June 2, 2026, recording now available Read Post »

World Health Organization opens public consultation on its first global strategy for organ donation and transplant, deadline August 31st 2026

The World Health Organization (WHO) has opened public consultation (until 31 August 2026) on its first draft global strategy for donation and transplantation of human cells, tissues and organs — following up on World Health Organization resolution 77.4 (2024). Key points: Who should participate Policy makers, regulators, service developers-providers, professional bodies, clinical and technical experts, scientists

World Health Organization opens public consultation on its first global strategy for organ donation and transplant, deadline August 31st 2026 Read Post »

Pulmonary Arterial Hypertension: How far we’ve come—and what’s next, Circulation, July 13, 2026

Over the past 40 years, treatment for pulmonary arterial hypertension (PAH) has changed dramatically. What was once considered a disease with very few treatment options is now managed with a growing range of therapies that help people live longer and enjoy a better quality of life. A review recently published in Circulation looks back at

Pulmonary Arterial Hypertension: How far we’ve come—and what’s next, Circulation, July 13, 2026 Read Post »

Patient advocate Natalia Maeva at the European Respiratory Society (ERS) Presidential Summit, Warsaw 2026

Natalia Maeva, a patient advocate for pulmonary hypertension, attended the European Respiratory Society (ERS) Presidential Summit in Warsaw in June 2026, participating in sessions on early detection, air quality, tobacco control, climate change and lung health. Having had her own life transformed by access to specialised treatment and lung transplantation, she found the discussions on

Patient advocate Natalia Maeva at the European Respiratory Society (ERS) Presidential Summit, Warsaw 2026 Read Post »

The e-book for the May 2026 edition of Transplant International is available online in open access

The e-book for the May 2026 edition of Transplant International is available online in open access at this link The cover features a letter to the editors reporting the impressive summiting of Aconcagua, the highest peak in the Americas, without supplemental oxygen by a lung transplant recipient accompanied by the medico-surgical team from Medical University

The e-book for the May 2026 edition of Transplant International is available online in open access Read Post »

Eight months, 230 days,11 countries, 20,000+ km. Lukáš Jakovec’s solo cycling journey for the AfPH “Wheels of Hope” campaign to raise awareness of organ donation and transplant now wraps up!

Lukáš Jakovec set off from Udine, Italy, on 11 October 2025 — a trip he had been planning for over seven years. Two hundred and thirty days and 22,000 km later, with a total elevation gain of roughly 144,000 metres, he rolled into Prague, his home town. Along the way he looped through Italy, including

Eight months, 230 days,11 countries, 20,000+ km. Lukáš Jakovec’s solo cycling journey for the AfPH “Wheels of Hope” campaign to raise awareness of organ donation and transplant now wraps up! Read Post »

Could sotatercept treatment be effective in patients with end-stage bronchiolitis obliterans syndrome after lung transplantation? Journal of Heart and Lung Transplant, August 2026 edition

Bronchiolitis obliterans syndrome (BOS) is the most common form of chronic lung allograft dysfunction after lung transplant, marked by progressive small airway disease with limited treatment options. This case report describes a 55-year-old woman with primary ciliary dyskinesia, post-bilateral lung transplant, who developed severe (stage 3) bronchiolitis obliterans syndrome and went into respiratory failure requiring

Could sotatercept treatment be effective in patients with end-stage bronchiolitis obliterans syndrome after lung transplantation? Journal of Heart and Lung Transplant, August 2026 edition Read Post »

What’s new in pulmonary hypertension on the Knowldge Sharing Platform, May 2026

This month’s selection reflects the remarkable momentum in the pulmonary hypertension field — from landmark regulatory approvals and cutting-edge research to inspiring human stories and practical tools for patients. As always, we have curated a range of content to inform, inspire, and empower our community. RESEARCH AND SCIENCE INDUSTRY NEWS DIGITAL HEALTH AND INNOVATION TRANSPLANT

What’s new in pulmonary hypertension on the Knowldge Sharing Platform, May 2026 Read Post »

“Transplantation Roadmap: Understanding the Role of Risk Assessment in Your Pulmonary Hypertension Plan”, June 2, 2026, 3 p.m. EDT

The Pulmonary Hypertension Association, PHA, is hosting a free webinar on transplant evaluation for people living with pulmonary hypertension and their caregivers. The session will cover how risk assessment works, how risk scores guide transplant referral and timing, and what questions to ask your care team — with perspectives on both adult and paediatric patients.

“Transplantation Roadmap: Understanding the Role of Risk Assessment in Your Pulmonary Hypertension Plan”, June 2, 2026, 3 p.m. EDT Read Post »

TRANSLATE »
Scroll to Top